Desh Rakshak Aushdhalaya Ltd
₹ 23.2
-4.97%
04 Mar
- close price
About
Incorporated in 1901, Desh Rakshak Aushdhalaya Ltd manufactures Ayurvedic and Herbal Products[1]
Key Points
- Market Cap ₹ 13.2 Cr.
- Current Price ₹ 23.2
- High / Low ₹ 95.1 / 23.2
- Stock P/E 21.0
- Book Value ₹ 22.6
- Dividend Yield 0.00 %
- ROCE 6.89 %
- ROE 4.94 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Stock is trading at 1.02 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 4.08% over past five years.
- Company has a low return on equity of 4.85% over last 3 years.
- Company has high debtors of 434 days.
- Promoter holding has decreased over last 3 years: -14.2%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.97 | 4.44 | 4.98 | 5.05 | 5.05 | 5.51 | 5.06 | 6.56 | 6.14 | 6.13 | 5.95 | 6.18 | 8.04 | |
| 3.39 | 3.79 | 4.26 | 4.39 | 4.34 | 4.73 | 4.27 | 5.61 | 4.94 | 4.74 | 4.66 | 4.92 | 6.30 | |
| Operating Profit | 0.58 | 0.65 | 0.72 | 0.66 | 0.71 | 0.78 | 0.79 | 0.95 | 1.20 | 1.39 | 1.29 | 1.26 | 1.74 |
| OPM % | 14.61% | 14.64% | 14.46% | 13.07% | 14.06% | 14.16% | 15.61% | 14.48% | 19.54% | 22.68% | 21.68% | 20.39% | 21.64% |
| 0.01 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 | -0.05 | 0.02 | 0.03 | 0.01 | |
| Interest | 0.08 | 0.12 | 0.11 | 0.11 | 0.13 | 0.13 | 0.16 | 0.16 | 0.24 | 0.42 | 0.37 | 0.31 | 0.41 |
| Depreciation | 0.39 | 0.45 | 0.24 | 0.22 | 0.24 | 0.25 | 0.27 | 0.26 | 0.40 | 0.44 | 0.44 | 0.42 | 0.61 |
| Profit before tax | 0.12 | 0.08 | 0.38 | 0.34 | 0.35 | 0.41 | 0.37 | 0.55 | 0.57 | 0.48 | 0.50 | 0.56 | 0.73 |
| Tax % | 41.67% | 75.00% | 23.68% | 17.65% | 20.00% | 19.51% | 18.92% | 23.64% | 15.79% | 14.58% | 16.00% | 16.07% | |
| 0.07 | 0.02 | 0.29 | 0.28 | 0.28 | 0.34 | 0.30 | 0.42 | 0.48 | 0.41 | 0.43 | 0.48 | 0.63 | |
| EPS in Rs | 0.16 | 0.05 | 0.65 | 0.63 | 0.63 | 0.77 | 0.68 | 0.95 | 1.08 | 0.92 | 0.97 | 1.08 | 1.34 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 4% |
| 3 Years: | 0% |
| TTM: | 21% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 37% |
| 5 Years: | 10% |
| 3 Years: | 0% |
| TTM: | 21% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 42% |
| 3 Years: | 65% |
| 1 Year: | -25% |
| Return on Equity | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 5% |
| 3 Years: | 5% |
| Last Year: | 5% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.66 | 4.66 | 4.66 | 4.66 | 4.66 | 4.66 | 4.66 | 4.66 | 4.66 | 4.66 | 4.66 | 4.66 | 5.92 |
| Reserves | 2.13 | 2.15 | 2.46 | 2.74 | 3.02 | 3.45 | 3.72 | 4.14 | 4.62 | 4.47 | 4.82 | 5.29 | 6.98 |
| 0.99 | 1.06 | 1.47 | 0.69 | 0.96 | 1.23 | 2.03 | 2.90 | 4.31 | 4.10 | 2.78 | 3.04 | 2.14 | |
| 1.55 | 1.71 | 1.49 | 2.07 | 2.16 | 2.01 | 1.91 | 2.87 | 2.53 | 2.51 | 4.06 | 4.99 | 4.42 | |
| Total Liabilities | 9.33 | 9.58 | 10.08 | 10.16 | 10.80 | 11.35 | 12.32 | 14.57 | 16.12 | 15.74 | 16.32 | 17.98 | 19.46 |
| 3.61 | 3.69 | 3.75 | 3.87 | 3.93 | 4.39 | 5.38 | 6.49 | 7.82 | 8.07 | 7.68 | 7.84 | 7.96 | |
| CWIP | 1.35 | 1.35 | 2.37 | 2.37 | 2.37 | 2.37 | 2.37 | 2.37 | 2.37 | 2.37 | 2.37 | 1.87 | 1.87 |
| Investments | 0.18 | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 |
| 4.19 | 4.42 | 3.84 | 3.80 | 4.38 | 4.47 | 4.45 | 5.66 | 5.88 | 5.25 | 6.22 | 8.22 | 9.58 | |
| Total Assets | 9.33 | 9.58 | 10.08 | 10.16 | 10.80 | 11.35 | 12.32 | 14.57 | 16.12 | 15.74 | 16.32 | 17.98 | 19.46 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.46 | 0.27 | 1.27 | 0.23 | -0.15 | -0.55 | 0.59 | 0.84 | 0.23 | 0.45 | 1.52 | -0.30 | |
| -0.33 | -0.45 | -0.66 | -0.76 | 0.04 | 0.42 | -1.27 | -1.26 | -1.95 | -0.78 | -0.09 | -0.02 | |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.00 | 0.74 | 0.80 | 1.35 | 0.15 | -1.34 | 0.25 | |
| Net Cash Flow | 0.13 | -0.18 | 0.61 | -0.53 | -0.04 | -0.12 | 0.06 | 0.37 | -0.36 | -0.18 | 0.09 | -0.07 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 117.68 | 127.42 | 125.33 | 146.72 | 179.25 | 196.08 | 221.45 | 214.77 | 236.00 | 216.74 | 314.70 | 434.10 |
| Inventory Days | 225.14 | 215.33 | 160.82 | 191.55 | 193.41 | 120.33 | 123.23 | 72.16 | 117.52 | 107.51 | 46.01 | 29.26 |
| Days Payable | 250.72 | 247.41 | 195.79 | 242.83 | 257.39 | 219.27 | 249.57 | 270.87 | 315.23 | 301.29 | 584.31 | 726.92 |
| Cash Conversion Cycle | 92.10 | 95.35 | 90.37 | 95.44 | 115.26 | 97.14 | 95.11 | 16.06 | 38.29 | 22.96 | -223.60 | -263.56 |
| Working Capital Days | 176.52 | 180.03 | 94.55 | 117.81 | 148.89 | 153.02 | 162.30 | 117.40 | 164.07 | 149.45 | 108.58 | 174.82 |
| ROCE % | 2.59% | 2.56% | 5.95% | 5.40% | 5.74% | 6.01% | 5.37% | 6.42% | 6.41% | 7.08% | 6.83% | 6.89% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover Ratio Times |
|
||||||||||
| Installed Capacity - Awaleha Tonnes |
|||||||||||
| Installed Capacity - Liquid Lacs Bottles |
|||||||||||
| Installed Capacity - Pills Lacs Nos. |
|||||||||||
| Installed Capacity - Tablets Lacs Nos. |
|||||||||||
| Total Permanent Employees Count |
|||||||||||
Requires Premium
Requires Premium
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
14 Feb - Company hereby submit Newspaper publication of Financial Results for the quarter and nine months ended December 31, 2025
-
Statement Of No Deviation(S) Or Variation(S) In The Use Of Proceeds And Utilization Of Funds Relating To Allotment Of Equity Shares On Preferential Basis Under Regulation 32 Of The SEBI (LODR) Regulations, 2015
13 Feb - No deviation: Rs2.77 crore raised Sep 9, 2025; proceeds fully utilized for working capital and general corporate purposes.
- Submission Of Unaudited Financial Results For The Quarter And Nine Months Ended 31St December, 2025 As Per Regulation 33 Of The SEBI (LODR), Regulations, 2015 13 Feb
-
Board Meeting Outcome for Outcome Of Board Meeting Held On Friday, 13Th Day Of February, 2026 Meeting Commenced At 01:00 P.M. And Concluded At 02:00 P.M Pursuant To Para A Of Part A Of Schedule III And Regulation 30 Of The SEBI (LODR) Regulations, 2015
13 Feb - Board approved unaudited results for quarter and nine-months to 31-Dec-2025: Q3 profit Rs 9.34 lakh; YTD profit Rs 26.72 lakh.
-
Board Meeting Intimation for Pre Intimation Of The Board Meeting As Per Regulation 29 Of The SEBI (LODR) Reg, 2015
9 Feb - Board meeting Feb 13, 2026 to approve unaudited results for quarter/nine months ended Dec 31, 2025.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Overview:[1][2]
DRAL is the flagship company of Bhagwant Group and one of the oldest manufacturers of Pure Ayurvedic and Herbal Products. It has a wide range of ethical medicines that are derived from herbs and form part of this holistic healthcare system. The medicines are categorized into Proprietary & Classical Medicines. The company is currently manufacturing around 450 products which are GMP certified.